Guiding Obstetric Care and Treatment Decisions for Women With Prior GLP-1 Receptor Agonist Use

Glucagon-like peptide-1 receptor agonists (GLP-1RAs), such as liraglutide and semaglutide, have revolutionized treatment of obesity. Obesity and obesity-related comorbidities increase the risks of adverse outcomes such as miscarriage, congenital malformations, preterm birth, gestational diabetes, and preeclampsia, which can have significant long-term consequences for mother and infant. By enabling women to begin pregnancy at a lower body mass index (BMI), GLP-1RAs have great potential to reduce these risks.